BASI - Bioanalytical Systems, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.57
-0.48 (-7.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.05
Open6.18
Bid5.01 x 1000
Ask9.20 x 900
Day's Range5.53 - 6.26
52 Week Range1.30 - 6.50
Volume77,275
Avg. Volume66,017
Market Cap58.545M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateFeb 11, 2020 - Feb 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.15
  • GlobeNewswire

    BASi Closes Fiscal 2019 with Strong Fourth Quarter

    WEST LAFAYETTE, Ind., Dec. 23, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) doing business as Inotiv, a leading provider of.

  • GlobeNewswire

    Inotiv, a BASi Company, Announces Closing of Pre-Clinical Research Services Transaction, Including New Financing to Fund the Transaction and Expand Discovery and DMPK Business

    In connection with the closing, the Company also closed on additional funding, which positions the Company to make future investments in organic growth in the drug metabolism and pharmacokinetics arena. The Company, which recently announced the rebranding of the Company’s contract research services business under the name Inotiv, closed on the PCRS business on December 1, 2019.

  • GlobeNewswire

    BASi Launches Rebrand of its Contract Research Services Business Under the Name Inotiv

    Inotiv represents the union of Bioanalytical Systems, Inc.’s (BASi’s), Seventh Wave Laboratories’, and Smithers Avanza Toxicology Services’ in vivo toxicology, pharmacology, drug metabolism, bioanalysis, and pharmacokinetic (PK) solutions, as well as the Company’s expansion into surgical and medical device contract research services with the expected acquisition of the Pre-Clinical Research Services business. The rebrand reflects the Company’s increased scope of services and its resulting position as a top contract research organization (CRO) for drug discovery and development.

  • GlobeNewswire

    BASi Announces Expansion into Surgical Models and Medical Devices with Agreement to Purchase Pre-Clinical Research Services

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a leading provider of nonclinical and analytical contract research services, today announced that the Company has entered into an agreement to purchase substantially all of the assets of Pre-Clinical Research Services, Inc. (“PCRS”), a premier provider of surgical and medical device contract research services. “We have great respect for the people and services provided by PCRS, and believe the current facilities in Ft. Collins, Colorado, will be an excellent location for future growth,” said Bob Leasure, BASi’s President and Chief Executive Officer.

  • The Bioanalytical Systems (NASDAQ:BASI) Share Price Is Up 521% And Shareholders Are Delighted
    Simply Wall St.

    The Bioanalytical Systems (NASDAQ:BASI) Share Price Is Up 521% And Shareholders Are Delighted

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...

  • GlobeNewswire

    Stewart B. Jacobson, DVM, DACVP, Joins BASi as Vice President, Pathology, Filling Key Scientific Leadership Position

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce the addition of Stewart B. Jacobson, DVM, DACVP, as Vice President, Pathology, effective October 1, 2019. Dr. Jacobson is an accomplished executive, skilled in strategic leadership, and brings over eighteen years of experience to the Company.

  • Does Bioanalytical Systems (NASDAQ:BASI) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Bioanalytical Systems (NASDAQ:BASI) Have A Healthy Balance Sheet?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    William D. Pitchford Joins BASi as Chief Human Resources Officer, as the Company Invests in Unifying and Strengthening Corporate Culture

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce the addition of William D. Pitchford, BS, MA, as Chief Human Resources Officer, effective as of August 28, 2019. Mr. Pitchford fills an important leadership position, as the Company invests in unifying and strengthening its corporate culture following the acquisition of Seventh Wave Laboratories in July of last year and, more recently, the Smithers Avanza Toxicology Services business unit in May.

  • What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. (NASDAQ:BASI)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. (NASDAQ:BASI)?

    The big shareholder groups in Bioanalytical Systems, Inc. (NASDAQ:BASI) have power over the company. Large companies...

  • GlobeNewswire

    BASi Continues Revenue Growth in Third Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., Aug. 14, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three and nine.

  • GlobeNewswire

    Bioanalytical Systems to Release Third Quarter Fiscal 2019 Results on Wednesday, August 14, 2019

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the third quarter of fiscal 2019 ended June 30, 2019, prior to the market opening on Wednesday, August 14, 2019. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.

  • Is Bioanalytical Systems, Inc.'s (NASDAQ:BASI) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.

    Is Bioanalytical Systems, Inc.'s (NASDAQ:BASI) Balance Sheet Strong Enough To Weather A Storm?

    Bioanalytical Systems, Inc. (NASDAQ:BASI) is a small-cap stock with a market capitalization of US$21m. While investors...

  • GlobeNewswire

    Researchers Generate Better Data with BASi’s Redesigned Raturn™

    Used as an alternative to liquid swivels or commutators, the Raturn™ interactively responds to animal movement to keep wires, tubing, fluid lines, optic and electrical cables from twisting. BASi’s Raturn™ systems are used in academic research, pharmaceutical laboratories, and CROs for a wide range of applications, including in vivo microdialysis, blood collection, optogenetics, ECG studies, blood pressure, and activity monitoring. “The objective of the Raturn™ is to help researchers obtain better data by simplifying sample collection while minimizing stress to the animal,” said Lauren Elolf, PhD, BASi’s Products Business Development Manager.  “It’s a great product, but we knew we could make it even better. The Raturn™ is compatible with BASi’s current line of cage options and integrates with a number of existing products, further strengthening the Company’s portfolio to generate better data while enhancing animal welfare—all at a reasonable price.

  • GlobeNewswire

    BASi Continues Revenue Growth in Second Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., May 15, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three and six.

  • GlobeNewswire

    Bioanalytical Systems to Release Second Quarter Fiscal 2019 Results on Wednesday, May 15, 2019

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that it will report financial results for the second quarter of fiscal 2019 ended March 31, 2019, prior to the market opening on Wednesday, May 15, 2019. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.

  • GlobeNewswire

    CORRECTED PRESS RELEASE: BASi Acquires the Smithers Avanza Toxicology Services Business Unit to Support Growing Toxicology Business and Broaden Scientific Talent

    This press release corrects a prior version published on May 1, 2019, and is updated to revise the amount of one of the loans previously reported. WEST LAFAYETTE, Ind., May 1, 2019 -- Bioanalytical Systems, Inc., (NASDAQ:BASI) (“BASi” or the “Company”) today announced its acquisition of the Smithers Avanza Toxicology Services business unit, a contract research organization (CRO) located in Gaithersburg, Maryland, which specializes in general toxicology, vaccine safety and developmental and reproductive toxicology (DART) studies, in support of pharmaceutical and chemical industry research and development.

  • GlobeNewswire

    BASi Acquires the Smithers Avanza Toxicology Services Business Unit to Support Growing Toxicology Business and Broaden Scientific Talent

    Bioanalytical Systems, Inc., (NASDAQ:BASI) (“BASi” or the “Company”) today announced its acquisition of the Smithers Avanza Toxicology Services business unit, a contract research organization (CRO) located in Gaithersburg, Maryland, which specializes in general toxicology, vaccine safety and developmental and reproductive toxicology (DART) studies, in support of pharmaceutical and chemical industry research and development. The acquired business will operate as a wholly owned subsidiary of BASi under the name BASi Gaithersburg.

  • Can You Imagine How Bioanalytical Systems's (NASDAQ:BASI) Shareholders Feel About The 97% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Bioanalytical Systems's (NASDAQ:BASI) Shareholders Feel About The 97% Share Price Increase?

    By buying an index fund, investors can approximate the average market return. But if you pick the right individual stocks, you could make more than that. Just take a look at Bioanalytical Systems, Inc. (NASDAQ:BASI), which is...

  • Does Bioanalytical Systems, Inc. (NASDAQ:BASI) Have A Volatile Share Price?
    Simply Wall St.

    Does Bioanalytical Systems, Inc. (NASDAQ:BASI) Have A Volatile Share Price?

    Anyone researching Bioanalytical Systems, Inc. (NASDAQ:BASI) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...

  • GlobeNewswire

    J. Scott Daniels, PhD, Joins BASi as Senior Vice President of DMPK, Filling Key Scientific Leadership Position

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce the addition of J. Scott Daniels, PhD, as Senior Vice President of DMPK, effective as of March 1, 2019. Dr. Daniels fills a strategic scientific leadership position within the Company that in recent months has made other key appointments to its organizational leadership following its acquisition of Seventh Wave Laboratories in July of last year.

  • GlobeNewswire

    BASi Appoints Joe Flynn as Chief Commercial Officer

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce that Joe Flynn has been appointed as Chief Commercial Officer of the Company, effective as of February 21, 2019. Mr. Flynn will be responsible for leading sales and marketing efforts across BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri. Mr. Flynn has an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development.

  • GlobeNewswire

    BASi Appoints Senior Contract Research Executive, D. Thomas Oakley, as Chief Operating Officer

    Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce that D. Thomas “Tom” Oakley has been appointed as Chief Operating Officer of the Company, effective as of February 11, 2019. Mr. Oakley will be responsible for leading operations among BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri. Mr. Oakley is a distinguished senior executive with over 20 years of strategic and operational experience in the contract research industry.

  • GlobeNewswire

    BASi Reports Revenue Growth in First Quarter of Fiscal 2019

    WEST LAFAYETTE, Ind., Feb. 14, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We” or “Our”) today announced financial results for the three months.

  • GlobeNewswire

    Bioanalytical Systems to Release First Quarter Fiscal 2019 Results on Thursday, February 14, 2019

    WEST LAFAYETTE, Ind., Feb. 12, 2019 -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced today that it will report financial results for the.